BPC-157 Dosage Guide
Study-derived doses from published human and preclinical research. All data is presented as "the dose used in Study X" — not as a recommendation for human use.
Research reference only. BPC-157 is not FDA-approved for human use. This guide summarises peer-reviewed scientific literature. It does not constitute medical advice. See our full disclaimer.
At a Glance
Source: Cekin AH et al., J Inflamm Res, 2021. PMID 34238945
Human Study Data
Note: Human Phase II data for BPC-157 is limited. This pilot study represents the most-cited human dosing reference. The majority of the BPC-157 evidence base consists of animal and preclinical research.
View on PubMed →Preclinical Research Data
The bulk of BPC-157 research is preclinical (rat and mouse models). Animal doses are not directly translatable to humans due to differences in metabolism, body composition, and route of administration.
Reconstitution for Research Use
BPC-157 is supplied as a lyophilised powder and must be reconstituted with bacteriostatic water (sterile water for injection with 0.9% benzyl alcohol) before use. Bacteriostatic water is preferred over plain sterile water because the preservative extends in-use stability.
Example preparation (5 mg vial)
Add 1 mL bacteriostatic water → concentration 5,000 mcg/mL (5 mcg/µL)
Add 2 mL bacteriostatic water → concentration 2,500 mcg/mL (2.5 mcg/µL)
Store reconstituted peptide at 2–8°C. Use within 4–8 weeks. Protect from light.
Frequently Asked Questions
What dose of BPC-157 was used in human clinical studies?
The primary human Phase II pilot study (Cekin AH et al., J Inflamm Res, 2021; PMID 34238945) used 250 mcg and 500 mcg once daily via subcutaneous injection over 4 weeks in patients with inflammatory bowel disease. This is the most directly cited human dosing reference available. Most BPC-157 research remains preclinical.
What dose of BPC-157 was used in animal research?
Pevec D et al. (J Orthop Res, 2001; PMID 11551553) used 10 mcg/kg and 10 ng/kg via intraperitoneal injection once daily for 7–14 days in rat tendon and muscle healing models. Animal doses are not directly translatable to humans.
How is BPC-157 reconstituted for research use?
BPC-157 lyophilised powder is typically reconstituted with bacteriostatic water. Adding 1 mL to a 5 mg vial yields 5,000 mcg/mL; adding 2 mL yields 2,500 mcg/mL. Use the Clinical Peptide reconstitution calculator for exact volumes based on your target dose.
What is BPC-157's regulatory and compounding status?
BPC-157 is under active FDA review. It was nominated for the July 23–24, 2026 FDA PCAC meeting for potential 503A Category 1 designation. It is not FDA-approved but also not on the explicitly prohibited list for research reagent use. See the PCAC 2026 tracker for current status.